Scribe shares surge in public market debut with Eli Lilly and Sanofi as backers
NEW YORK, July 24. Shares of Scribe surged during the company's public market debut, the release shows. Scribe is backed by Eli Lilly (LLY) and Sanofi.
Key takeaways
- Shares of Scribe surged on the company's first day of public trading.
- Scribe is backed by pharmaceutical companies Eli Lilly (ticker LLY) and Sanofi.
- Both Eli Lilly and Sanofi held positions in Scribe when it entered public markets.
- The source does not disclose Scribe's opening price, trading range, or percentage gain from the debut session.
- No pricing details, financial terms, or statements from Scribe, Eli Lilly, or Sanofi were available at the time of publication.
NEW YORK, July 24. Shares of Scribe surged during the company's public market debut, the release shows. Scribe is backed by Eli Lilly (LLY) and Sanofi.
Pharmaceutical investors at the listing
Scribe's investor base includes Eli Lilly, which trades under the ticker LLY, and Sanofi. Both companies held positions in Scribe when it entered public markets. The source does not disclose the opening price, trading range, or percentage gain recorded on the debut session.
Opening-day performance
Scribe's share price climbed on its first day of public trading, according to the source. No pricing details, financial terms, or statements attributed to Scribe, Eli Lilly, or Sanofi were available in the source material at time of publication.
The source provided contains only the facts reported above. Extending this article to 350 words would require inventing prices, percentages, or other specifics absent from the source. Per standing desk policy, the piece runs at accurate length rather than padded length.